

Title (en)
Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4

Title (de)
Behandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4

Title (fr)
Traitement de cancer par l'anticorps rhuMAb 2C4

Publication
EP 1585966 B1 20111130 (EN)

Application
EP 03755724 A 20030711

Priority
• US 0321590 W 20030711
• US 39629002 P 20020715
• US 48004303 P 20030620

Abstract (en)
[origin: WO2004008099A2] Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.

IPC 8 full level
A61K 39/395 (2006.01); **C07K 14/485** (2006.01); **C07K 16/32** (2006.01); **G01N 33/50** (2006.01); **G01N 33/53** (2006.01); **G01N 33/574** (2006.01)

CPC (source: EP US)
A61P 35/00 (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/32** (2013.01 - EP US); **G01N 33/57492** (2013.01 - EP US); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US); **G01N 2333/485** (2013.01 - EP US); **G01N 2333/71** (2013.01 - EP US); **G01N 2800/52** (2013.01 - EP US)

Citation (examination)
• GORDON MICHAEL S ET AL: "Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 24, no. 26, 10 September 2006 (2006-09-10), pages 4324 - 4332, XP002492090, ISSN: 0732-183X, [retrieved on 20060807], DOI: 10.1200/JCO.2005.05.4221
• BASELGA, J. ET AL.: "Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which as progressed during treatment with T", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June 2007 (2007-06-20), pages 1004
• MAKHIJA, S. ET AL.: "Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June 2007 (2007-06-20), pages 5507
• CHEE M NG ET AL: "Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 23, no. 6, 26 May 2006 (2006-05-26), pages 1275 - 1284, XP019405128, ISSN: 1573-904X, DOI: 10.1007/S11095-006-0205-X
• ALLISON, D. ET AL.: "Pharmacokinetics (PK) of Pertuzumab (rhuMAb 2C4) in Phase II Studies of Ovarian, Breast, Prostate, and Lung Cancers", 2005, pages 2532

Cited by
EP1846030B1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004008099 A2 20040122; WO 2004008099 A3 20050901; WO 2004008099 A8 20050217; AT E535254 T1 20111215; AU 2003273218 A1 20040202; AU 2003273218 B2 20091126; AU 2003273218 C1 20190117; AU 2010200692 A1 20100318; BR 0312534 A 20070313; CA 2490758 A1 20040122; CA 2490758 C 20140923; CN 101711866 A 20100526; CN 102295703 A 20111228; CY 1112631 T1 20160210; CY 1113260 T1 20160413; DK 1585966 T3 20120220; DK 2263691 T3 20121022; EP 1585966 A2 20051019; EP 1585966 A4 20070221; EP 1585966 B1 20111130; EP 1585966 B8 20120307; EP 2263691 A1 20101222; EP 2263691 B1 20120829; ES 2376165 T3 20120309; ES 2392525 T3 20121211; HK 1082687 A1 20060616; HU P0600340 A2 20060828; HU P0600340 A3 20110628; IL 165952 A0 20060115; IL 165952 A 20120628; IL 219381 A0 20120628; IL 219381 A 20141130; JP 2006508336 A 20060309; JP 2012232987 A 20121129; JP 2014237667 A 20141218; JP 5069843 B2 20121107; JP 5678005 B2 20150225; MX PA05000403 A 20050722; NO 20050775 L 20050214; NO 337855 B1 20160704; NZ 537660 A 20081224; PL 214010 B1 20130628; PL 377743 A1 20060220; PT 1585966 E 20120220; PT 2263691 E 20121112; RU 2005103824 A 20050827; RU 2008128244 A 20100120; RU 2338751 C2 20081120; US 2004106161 A1 20040603; US 2011117096 A1 20110519

DOCDB simple family (application)
US 0321590 W 20030711; AT 03755724 T 20030711; AU 2003273218 A 20030711; AU 2010200692 A 20100225; BR 0312534 A 20030711; CA 2490758 A 20030711; CN 200910207004 A 20030711; CN 201110278830 A 20030711; CY 121100167 T 20120217; CY 121101025 T 20121029; DK 03755724 T 20030711; DK 10176072 T 20030711; EP 03755724 A 20030711; EP 10176072 A 20030711; ES 03755724 T 20030711; ES 10176072 T 20030711; HK 06104646 A 20060419; HU P0600340 A 20030711; IL 16595204 A 20041223; IL 21938112 A 20120424; JP 2004521625 A 20030711; JP 2012145330 A 20120628; JP 2014144190 A 20140714; MX PA05000403 A 20030711; NO 20050775 A 20050214; NZ 53766003 A 20030711; PL 37774303 A 20030711; PT 03755724 T 20030711; PT 10176072 T 20030711; RU 2005103824 A 20030711; RU 2008128244 A 20080710; US 61975403 A 20030714; US 95572710 A 20101129